Ukrainskaya VM, Bobik TV, Argentova-Stevens A, Slutskaya EA, Kalinin RS, Gabibov AG, Stepanov AV. Directed Change in TNFα Specificity to Create DR5 Antagonists.
Bull Exp Biol Med 2018;
165:386-389. [PMID:
30003423 DOI:
10.1007/s10517-018-4176-9]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Indexed: 12/01/2022]
Abstract
Death receptor 5 (DR5) is a promising target for antitumor therapy due to its high expression on different tumor cells. Resistance of various tumor cells against TRAIL, a natural ligand for the death receptors, reduces its therapeutic potential and prompts the search for novel agonists at these receptors. Previous screening across the combinatorial peptide library yielded a peptide sequence KVVLTHR that specifically binds DR5. Incorporation of this sequence into TNFα resulted in binding DR5 with mutant protein TNFα-mut and appearance of cytotoxicity against lymphoma cells.
Collapse